206124-50-7Relevant academic research and scientific papers
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
Miller, William H.,Bondinell, William E.,Cousins, Russell D.,Erhard, Karl F.,Jakas, Dalia R.,Keenan, Richard M.,Ku, Thomas W.,Newlander, Kenneth A.,Ross, Stephen T.,Haltiwanger, R. Curtis,Bradbeer, Jeremy,Drake, Fred H.,Gowen, Maxine,Hoffman, Sandra J.,Hwang, Shing-Mei,James, Ian E.,Lark, Michael W.,Lechowska, Beata,Rieman, David J.,Stroup, George B.,Vasko-Moser, Janice A.,Zembryki, Denise L.,Azzarano, Leonard M.,Adams, Paula C.,Salyers, Kevin L.,Smith, Brian R.,Ward, Keith W.,Johanson, Kyung O.,Huffman, William F.
, p. 1807 - 1812 (2007/10/03)
A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis.
